Rx (Prescription Medicine)
USD $ 10.00
Bronchonib 150mg Capsule 是一种用于治疗特定类型非小细胞肺癌（NSCLC）的靶向疗法药物。其活性成分为吡达尼布（Nintedanib），属于酪氨酸激酶抑制剂，可通过阻断特定酶的活性，抑制癌细胞生长及供给肿瘤的血管形成。通过抑制这些通路，Bronchonib 有助于减缓或停止肺癌的进展。
Bronchonib 150mg Capsule 适用于已接受初始化疗后疾病进展的转移性或晚期非小细胞肺癌患者。它通常作为二线治疗方案处方。
Bronchonib 150mg Capsule 的常规剂量为 150mg，每日口服两次。每天服药时间应保持一致，可与食物同服或空腹服用。请勿压碎或咀嚼胶囊，整粒用水吞服。若漏服，应在记起的时间尽快服用，但若距下一次服药时间较近，则应跳过本次漏服，继续按原计划服用。
常见不良反应可能包括腹泻、恶心、呕吐、腹痛以及肝酶升高。严重不良反应可能发生，因此如出现任何新发或加重的症状，应立即告知医生。Bronchonib 应储存在室温，避免潮湿和热源，并置于儿童不易触及的地方。
| Molecule | |
|---|---|
| Strength | |
| Pack Quantity | |
| Medicine Form | |
| Medicine Type | |
| Rx Status | |
| Country Of Origin | |
| Packaging Type | |
| Brand Name |
其他品牌的 Nintedanib 150 Mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
